The Role of PIAS SUMO E3-Ligases in Cancer

Cancer Research

Volumn 77, Issue 7, 2017, Pages 1542-1547

  Rabellino, Andrea ^a,b,c   Andreani, Cristina ^a,b   Scaglioni, Pier Paolo ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN KINASE B; SUMO E3 LIGASE; SUMO PROTEIN; UNCLASSIFIED DRUG; MYC PROTEIN; MYC PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; UBIQUITIN PROTEIN LIGASE;

ADAPTIVE IMMUNITY; AUTOPHOSPHORYLATION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; DNA REPAIR; ENZYME SPECIFICITY; EPITHELIAL MESENCHYMAL TRANSITION; HEMATOPOIESIS; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; MALIGNANT NEOPLASM; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; SPATIAL LEARNING; STRUCTURAL HOMOLOGY; SUMOYLATION; UBIQUITINATION; ANIMAL; CELL MOTION; NEOPLASMS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN INHIBITORS OF ACTIVATED STAT; PROTO-ONCOGENE PROTEINS C-MYC; SUMOYLATION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 85017337605     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-2958     Document Type: Review

References (49)

1. Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, et al. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell 2005;9:769-79.
2. Flotho A, Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem 2013;82:357-85.
3. Hendriks IA, Vertegaal AC. A comprehensive compilation of SUMO proteomics. Nat Rev Mol Cell Biol 2016;17:581-95.
4. Liang YC, Lee CC, Yao YL, Lai CC, Schmitz ML, Yang WM. SUMO5, a novel poly-SUMOisoform, regulates PML nuclear bodies. Sci Rep 2016;6:26509.
5. Yunus AA, Lima CD. Structure of the Siz/PIAS SUMO E3 ligase Siz1 and determinants required for SUMO modification of PCNA. Mol Cell 2009;35:669-82.
6. Werner A, Flotho A, Melchior F. The RanBP2/RanGAP1 SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase. Mol Cell 2012;46:287-98.
7. Rytinki MM, Kaikkonen S, Pehkonen P, Jaaskelainen T, Palvimo JJ. PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol Life Sci 2009;66:3029-41.
8. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997;278:1803-5.
9. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A 1998;95:10626-31.
10. Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM, Jackson SP. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 2009;462:935-9.
11. Jang HD, Yoon K, Shin YJ, Kim J, Lee SY. PIAS3 suppresses NF-kappaBmediated transcription by interacting with the p65/RelA subunit. J Biol Chem 2004;279:24873-80.
12. Kotaja N, VihinenM, Palvimo JJ, Janne OA. Androgen receptor-interacting protein 3 and other PIAS proteins cooperate with glucocorticoid receptorinteracting protein 1 in steroid receptor-dependent signaling. J Biol Chem 2002;277:17781-8.
13. Morris JR, Boutell C, Keppler M, Densham R, Weekes D, Alamshah A, et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009;462:886-90.
14. Liu B, Tahk S, Yee KM, Fan G, Shuai K. The ligase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression. Science 2010;330:521-5.
15. Liu B, Yee KM, Tahk S, Mackie R, Hsu C, Shuai K. PIAS1 SUMO ligase regulates the self-renewal and differentiation of hematopoietic stem cells. EMBO J 2014;33:101-13.
16. Constanzo JD, Deng M, Rindhe S, Tang KJ, Zhang CC, Scaglioni PP. Pias1 is essential for erythroid and vascular development in the mouse embryo. Dev Biol 2016;415:98-110.
17. Tai DJ, Hsu WL, Liu YC, Ma YL, Lee EH. Novel role and mechanism of protein inhibitor of activated STAT1 in spatial learning. EMBO J 2011;30:205-20.
18. Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F, Grosschedl R. PIASy, a nuclear matrix-Associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 2001;15:3088-103.
19. Schmidt D, Muller S. Members of the PIAS family act asSUMOligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci U S A 2002;99:2872-7.
20. Stehmeier P, Muller S. Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol Cell 2009;33:400-9.
21. Rabellino A, Carter B, Konstantinidou G, Wu SY, Rimessi A, Byers LA, et al. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res 2012;72:2275-84.
22. Yao Q, Li H, Liu BQ, Huang XY, Guo L. SUMOylation-regulated protein phosphorylation, evidence from quantitative phosphoproteomics analyses. J Biol Chem 2011;286:27342-9.
23. Liu B, Yang Y, Chernishof V, Loo RR, Jang H, Tahk S, et al. Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1 to restrict inflammation and immunity. Cell 2007;129:903-14.
24. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
25. Kessler JD, Kahle KT, Sun T,Meerbrey KL, Schlabach MR, Schmitt EM, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012;335:348-53.
26. Puhr M, Hoefer J, Eigentler A, Dietrich D, van Leenders G, Uhl B, et al. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. Oncogene 2016;35:2322-32.
27. Hoefer J, Schafer G, Klocker H, Erb HH, Mills IG, Hengst L, et al. PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol 2012;180:2097-107.
28. Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, et al. The sumoylation pathway is dysregulated inmultiple myeloma and is associated with adverse patient outcome. Blood 2010;115:2827-34.
29. Stehmeier P, Muller S. Regulation of p53 familymembers by the ubiquitinlike SUMO system. DNA Repair 2009;8:491-8.
30. Miyauchi Y, Yogosawa S, Honda R, Nishida T, Yasuda H. Sumoylation of Mdm2by protein inhibitor of activated STAT (PIAS) and RanBP2 enzymes. J Biol Chem 2002;277:50131-6.
31. Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012;4:a011189.
32. Li R, Wei J, Jiang C, Liu D, Deng L, Zhang K, et al. Akt SUMOylation regulates cell proliferation and tumorigenesis. Cancer Res 2013;73: 5742-53.
33. de la Cruz-Herrera CF, Campagna M, Lang V, del Carmen Gonzalez-Santamaria J, Marcos-Villar L, Rodriguez MS, et al. SUMOylation regulates AKT1 activity. Oncogene 2015;34:1442-50.
34. Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T, et al.SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun 2012;3:911.
35. Kamitani T, Nguyen HP, Kito K, Fukuda-Kamitani T, Yeh ET. Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J Biol Chem 1998;273:3117-20.
36. Bernardi R, Pandolfi PP. A dialog on the first 20 years of PML research and the next 20 ahead. Front Oncol 2014;4:23.
37. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B, et al. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 2006;126:269-83.
38. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 2004;96:269-79.
39. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008;10:547-55.
40. de The H, Le Bras M, Lallemand-Breitenbach V. The cell biology of disease: acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol 2012;198:11-21.
41. Amati B. Myc degradation: dancing with ubiquitin ligases. Proc Natl Acad Sci U S A 2004;101:8843-4.
42. Sabo A, Doni M, Amati B. SUMOylation of Myc-family proteins. PLoS One 2014;9:e91072.
43. Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, et al. PIAS1 promotes lymphomagenesis through MYC upregulation. Cell Rep 2016;15:2266-78.
44. Gonzalez-Prieto R, Cuijpers SA, Kumar R, Hendriks IA, Vertegaal AC. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4. Cell Cycle 2015; 14:1859-72.
45. Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, et al. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood 2014;124:2081-90.
46. Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 2014;14:598-610.
47. Constanzo JD, Tang KJ, Rindhe S, Melegari M, Liu H, Tang X, et al. PIAS1-FAK interaction promotes the survival and progression of non-small cell lung cancer. Neoplasia 2016;18:282-93.
48. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178-96.
49. Licciardello MP, Kubicek S. Pharmacological treats for SUMO addicts. Pharmacol Res 2016;107:390-7.